摘要
目的探讨血管紧张素Ⅱ1型受体自体抗体(AT1-AAs)和α1-肾上腺素受体自体抗体(α1-AAs)与血压正常人群的动脉硬化进展的关系。方法收集816例体检者的临床资料,将体检时AT1-AAs和α1-AAs情况作为基线AT1-AAs和α1-AAs,使用颈-股动脉脉搏波传导速度(cfPWV)评估动脉硬化程度,进行5年随访,比较5年前后cfPWV水平。结果体检者男476例,女340例,年龄(39.1±7.8)岁。基线cfPWV为[(9.90±0.84)m/s],随访5年后cfPWV为[(10.51±1.12)m/s]。年平均cfPWV变化值(ΔcfPWV)为[(0.12±0.08)m·s^-1·y^-1]。随访结束时,研究对象确诊高血压129例,出现动脉硬化进展144例。调整多因素后的回归分析显示基线自体抗体类型与ΔcfPWV、年平均ΔcfPWV独立相关。Cox回归模型结果显示,基线自体抗体阳性的受试者高血压患病风险和动脉硬化进展风险明显高于自体抗体阴性的受试者(RR=3.883、3.606,95%CI:1.359~11.096、1.349~9.644,均P<0.05)。结论AT1-AAs和α1-AAs是血压正常人群的动脉硬化进展的独立危险因素。
Objective To investigate the correlation of autoantibodies against angiotensinⅡtype 1 receptor(AT1-AAs)and autoantibodies against alpha1-adrenergic receptor(α1-AAs)with arterial stiffness progression.Methods Total 816 subjects with normal blood pressure in health check-up were prospectively enrolled in the study.The AT1-AAs andα1-AAs levels were measured at baseline.Meanwhile,carotid femoral pulse wave velocity(cfPWV)was measured to assess the degree of arterial stiffness at baseline and after 5-year follow up.Results There were 476 males and 340 females with a mean baseline age of(39.1±7.8)years.The mean baseline cfPWV was(9.90±0.84)m/s and that of follow-up was(10.51±1.12)m/s with an annualizedΔcfPWV of(0.12±0.08)m·s^-1·y^-1.At the end of follow-up,129 subjects were diagnosed as hypertension and 144 had arterial stiffness progression.After adjusting for multiple factors,linear regression analysis showed that baseline autoantibody type was independently correlated withΔcfPWV and annualizedΔcfPWV.Multivariate Cox proportional hazards regression model showed that subjects with a positive baseline autoantibody had a significantly higher risk of hypertension and progression of arterial stiffness than subjects with a negative baseline autoantibody.Conclusion AT1-AAs andα1-AAs are independent predictors for progression of arterial stiffness in population with normal blood pressure.
作者
姚涛
王翠芳
张琦
徐露
崔琴
彭勃
高岩
李刚
YAO Tao;WANG Cuifang;ZHANG Qi(Departmentof Neurology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《浙江医学》
CAS
2019年第11期1119-1123,1137,共6页
Zhejiang Medical Journal
